This plain language summary breaks down the side effect management approaches used in the MonumenTAL-1 study, offering a comprehensive look at how researchers and clinicians addressed treatment-related considerations for multiple myeloma patients receiving talquetamab therapy.
Plain Language Summary
What is this summary about?
This summary describes side effects management in the MonumenTAL-1 clinical trial, testing the drug talquetamab in participants with relapsed/ refractory multiple myeloma.
What were the study results?
More than 70% of participants had their cancer get better or become undetectable, with some in remission for months or years. Some participants had side effects, with some linked to how talquetamab works. Adjustments to the dose or frequency of talquetamab…